Klas G. Wiman

18.2k citations

179 papers · 14.1k indexed · 3 hit papers · h-index 67

Molecular Biology top 0.5%
Oncology top 0.2%
Cancer Research top 0.5%
Immunology top 1%
Biotechnology top 0.1%

Co-authors: Vladimir J.N. Bykov Galina Selivanova Thierry Soussi László Székely Jan Bergman Sofi Eriksson Julie Bianchi Lars Rask
Topics: Cancer-related Molecular Pathways (120 papers)Epigenetics and DNA Methylation (32 papers)Ubiquitin and proteasome pathways (28 papers)
Cited by: Oncology Biotechnology Cancer Research
Journals: Nature Cell Proceedings of the National Academy of Sciences
Partner nations: Sweden France United States

In The Last Decade

Klas G. Wiman

178 papers receiving 13.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

2002 840 citations Vladimir J.N. Bykov, Jan Bergman et al. profile →
Targeting mutant p53 for efficient cancer therapy

2017 694 citations Vladimir J.N. Bykov, Sofi Eriksson et al. profile →
Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus

1984 234 citations Klas G. Wiman et al. profile →

Peers

Countries citing papers authored by Klas G. Wiman

Since Specialization

Citations

This map shows the geographic impact of Klas G. Wiman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klas G. Wiman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klas G. Wiman more than expected).

Fields of papers citing papers by Klas G. Wiman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klas G. Wiman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klas G. Wiman. The network helps show where Klas G. Wiman may publish in the future.

Co-authorship network of co-authors of Klas G. Wiman

This figure shows the co-authorship network connecting the top 25 collaborators of Klas G. Wiman. A scholar is included among the top collaborators of Klas G. Wiman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klas G. Wiman. Klas G. Wiman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic targeting of TP53 nonsense mutations in cancer 2024 ·Upsala Journal of Medical Sciences ·(unknown),Klas G. Wiman	3
2	Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene 2023 ·PLoS ONE ·(unknown),(unknown),Vladimir J.N. Bykov,Klas G. Wiman	4
3	Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN 2023 ·RNA Biology ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Jianping Liu,Vladimir J.N. Bykov,Klas G. Wiman	7
4	Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog 2022 ·Cell Death and Disease ·Qiang Zhang,(unknown),Bruno Baron,(unknown),Tali E. Haran,Klas G. Wiman,Thierry Soussi,Andreas C. Joerger	14
5	Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine 2022 ·Cell Death and Disease ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Birthe Meineke,Vladimir J.N. Bykov,Sebastiaan van Heesch,Klas G. Wiman	16
6	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells 2021 ·Cell Death and Disease ·Sophia Ceder,Sofi Eriksson,Ying Liang,(unknown),(unknown),Kenji M. Fujihara,Julie Bianchi,Vladimir J.N. Bykov,Lars Abrahmsén,Nicholas J. Clemons,P. Nordlund,Sean G. Rudd,Klas G. Wiman	12
7	Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene 2020 ·Cell Death and Differentiation ·(unknown),(unknown),(unknown),Bernard Leroy,Isabelle Martins,Johanna Sofia Margareta Mattsson,Patrick Micke,Šárka Pavlová,Šárka Pospı́šilová,Jana Šmardová,Andreas C. Joerger,Klas G. Wiman,Guido Kroemer,Thierry Soussi	22
8	A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death 2020 ·EMBO Molecular Medicine ·Sophia Ceder,Sofi Eriksson,(unknown),Swati Dawar,(unknown),Vladimir J.N. Bykov,Kenji M. Fujihara,(unknown),Xiaodun Li,Susanne Ramm,Corina Behrenbruch,Kaylene J. Simpson,Frédéric Hollande,Lars Abrahmsén,Nicholas J. Clemons,Klas G. Wiman	29
9	Functional characterization of novel germline TP53 variants in Swedish families 2019 ·Clinical Genetics ·Pedram Kharaziha,Sophia Ceder,(unknown),(unknown),(unknown),Stefanie Böhm,Sonia Laı́n,Åke Borg,Catharina Larsson,Klas G. Wiman,Emma Tham,Svetlana Bajalica‐Lagercrantz	9
10	Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246 2018 ·Scientific Reports ·(unknown),Jun Lu,Vladimir J.N. Bykov,(unknown),Xiaoyuan Ren,Lucia Coppo,Klas G. Wiman,Arne Holmgren	55
11	APR-246 reactivates mutant p53 by targeting cysteines 124 and 277 2018 ·Cell Death and Disease ·Qiang Zhang,Vladimir J.N. Bykov,Klas G. Wiman,Joanna Zawacka‐Pankau	186
12	The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells 2018 ·Translational Oncology ·Naoise C. Synnott,Stephen F. Madden,Vladimir J.N. Bykov,John Crown,Klas G. Wiman,Michael J. Duffy	27
13	Role of Thiol Reactivity for Targeting Mutant p53 2018 ·Cell chemical biology ·Qiang Zhang,Jan Bergman,Klas G. Wiman,Vladimir J.N. Bykov	17
14	Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation 2017 ·Nature Communications ·David S. Liu,Cuong Duong,Sue Haupt,Karen G. Montgomery,Colin M. House,Walid J. Azar,Helen Pearson,Oliver M. Fisher,Matthew Read,Glen Guerra,Ygal Haupt,Carleen Cullinane,Klas G. Wiman,Lars Abrahmsén,Wayne A. Phillips,Nicholas J. Clemons	260
15	Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy 2016 ·Frontiers in Oncology ·Vladimir J.N. Bykov,Qiang Zhang,(unknown),Sophia Ceder,Lars Abrahmsén,Klas G. Wiman	101
16	Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival 2009 ·Leukemia & lymphoma ·(unknown),(unknown),Bertil Uggla,Stefan Deneberg,Sofia Bengtzén,(unknown),Ingrid Dahlman,Richard Rosenquist,Klas G. Wiman,Hareth Nahi	4
17	Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis 2009 ·Oncogene ·Jérémy Lambert,Ali Moshfegh,Pierre Hainaut,Klas G. Wiman,Vladimir J.N. Bykov	85
18	PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain 2009 ·Cancer Cell ·Jérémy Lambert,(unknown),Dmitry B. Veprintsev,(unknown),Dan Segerbäck,Jan Bergman,Alan R. Fersht,Pierre Hainaut,Klas G. Wiman,Vladimir J.N. Bykov	450
19	Role of genetic and epigenetic changes in Burkitt lymphoma 2002 ·Seminars in Cancer Biology ·Mikael S. Lindström,Klas G. Wiman	75
20	p16/INK4a and p15/INK4b Gene Methylation and Absence of p16/INK4a mRNA and Protein Expression in Burkitt's Lymphoma 1998 ·Blood ·Ulf Klangby,İsmail Okan,Kristinn P. Magnússon,Martin Wendland,Peter Lind,Klas G. Wiman	74

About Klas G. Wiman

Klas G. Wiman is a scholar working on Oncology, Biotechnology and Molecular Biology, having authored 179 papers that have together received 14.1k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (120 papers), Epigenetics and DNA Methylation (32 papers) and Ubiquitin and proteasome pathways (28 papers). The work is most often cited by research in Oncology (7.0k citations), Biotechnology (1.6k citations) and Cancer Research (2.3k citations). Klas G. Wiman has collaborated with scholars based in Sweden, France and United States. Frequent co-authors include Vladimir J.N. Bykov, Galina Selivanova, Thierry Soussi, László Székely, Jan Bergman, Sofi Eriksson, Julie Bianchi, Lars Rask, Kristinn P. Magnússon and Pierre Hainaut. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact